Elizabeth Williams is the Chief Financial Officer of Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, where she has responsibility for all corporate finance and accounting functions. Ms. Williams joined Medicenna as a private company and led the public listings onto the TSX and subsequently NASDAQ. She has more than 15 years of experience in biotech, working with publicly listed entities in both Canada and the United States, and has played an integral role in raising more than $150 million in financings during this period.
Previously, Ms. Williams was the Vice President of Finance and Administration at Aptose Biosciences, Inc. a biotechnology company listed on both the TSX and NASDAQ, and began her career at Ernst & Young LLP. She is a CPA and CA and received a BBA from Wilfrid Laurier University.